Biotech Values

[DewDiligence]

IDIX cash balance and cash-usage guidance:

http://finance.yahoo.com/news/idenix-pharmaceuticals-reports-fourth-quarter-210500462.html

At December 31, 2013, Idenix's cash and cash equivalents totaled $122.0 million. The Company expects that its current cash and cash equivalents and the net proceeds from the January 2014 registered direct offering of $106.7 million will be sufficient to sustain its operations into at least the second half of 2015. This guidance excludes milestone payments or license fees, reimbursement for development programs and additional financing activities.

I.e. IDIX currently has $228.7M less whatever cash it has burned in 2014 to date.